Norsemont Drilling Program Update at Choquelimpie
VANCOUVER, BC, Feb. 20, 2026 /PRNewswire/ -- Norsemont Mining Inc. (CSE: NOM), (OTC: NRRSF), (FWB: LXZ1) ( " Norsemont "...
Read moreDetails
Uncategorized
GownCard Launches with Health System Partnerships to Improve Operating Room Readiness
NASHVILLE, Tenn., Feb. 20, 2026 /PRNewswire/ -- GownCard, a collaborative knowledge platform for surgical teams, today announced its official launch,...
Read moreDetails
Invitation to presentation of Sectra’s nine-month report 2025/2026
LINKÖPING, Sweden, Feb. 20, 2026 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) invites investors, analysts,...
Read moreDetailsEnphase Energy, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – ENPH
LOS ANGELES, Feb. 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Enphase...
Read moreDetailsInsulin Delivery Devices Market: 7.82% CAGR to 2031 Driven by Digital Insulin Pens and Pumps Transforming Diabetes Care, Says a 2026 Mordor Intelligence Report
HYDERABAD, India, Feb. 20, 2026 /PRNewswire/ -- According to the latest Mordor Intelligence report, the insulin delivery devices market size...
Read moreDetails
Ribbon Provides Edge Solutions for Salt’s Enterprise Voice Expansion
Innovative Swiss provider expands its business offerings with Ribbon's state of the art technologyPLANO, Texas, Feb. 20, 2026 /PRNewswire/ -- Ribbon...
Read moreDetails
Hankook’s Proven Top-Tier Rally Tire Technology Underpins Rally Sweden’s Safe Conclusion Across Relentless Snow and Ice
Round 2 Rally Sweden concluded in extreme winter conditions, with the entire route covered in snow and thick iceHankook's Winter...
Read moreDetailsClarins unveils the AI Shade Finder, the most precise ever foundation matcher
An exclusive AI-powered in-store service redefining personalized make-upPARIS, Feb. 20, 2026 /PRNewswire/ -- Faithful to its pioneering spirit since 1954, Clarins...
Read moreDetailsU.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY...
Read moreDetailstranscosmos conducts a Roblox-based Future Creator Development seminar in Wakayama
From play to creation. Verification and improvement cycle develops next-gen CX talentTOKYO, Feb. 20, 2026 /PRNewswire/ -- transcosmos supports Game...
Read moreDetails